Journal
GLP-1 and Tirzepatide Journal
The journal covers the things moving fastest in this market: compounding regulation, pricing practice, and clinical evidence. Seventeen pieces are published, each built on primary sources with an explicit section on what the evidence does not establish.
What this section is for
The rest of this site answers stable questions — what a drug costs, what a trial found, how to verify a pharmacy. The journal covers what is changing, which in this market is a great deal.
The single largest story is regulatory. The FDA's April 2026 proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list would close the last pathway permitting large-scale compounding of these molecules, and the comment period closes on 30 July 2026. Most coverage of this market has not registered it.
The second is commercial. Brand prices fell sharply in late 2025, and the cheapest FDA-approved GLP-1 for weight loss is now $149 a month — which undercuts most of the compounded market. Almost no comparison page has updated.
How these pieces are built
Every article cites the primary source: the agency's own notice, the registry entry, the peer-reviewed paper, or the provider's own page captured on a date. A news article about a study is not a source for that study's results.
Each carries an explicit section on what the evidence does not establish. That section is never cut for length, because it is usually the part that distinguishes a useful piece from a confident one.
Each carries at least one original figure — a chart, a matrix, a timeline or a process diagram — built from our own data rather than borrowed.
What we have not published, and why
Three commissioned pieces remain unwritten and are excluded from search indexing until they are.
The retatrutide phase 3 piece is the notable one. Figures circulating online — 28.3% at 80 weeks in TRIUMPH-1 — trace only to commercial secondary sources, at least one of which sells peptides. We have recorded the solid phase 2 NEJM citation and will not publish a phase 3 number until it is confirmed against the primary publication.
That is the same standard applied to every figure here, and it is the reason this section is shorter than it could be.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Published | 20 | 100% |
| Commissioned, unwritten | 0 | 0% |
Show this figure as a table
| Date | Event |
|---|---|
| 2022 | Tirzepatide added to the F |
| 2024-10 | FDA declared the tirzepati |
| 2025-02 | FDA declared the semagluti |
| 2025-09-16 | FDA issued 55+ warning let |
| 2026-02-09 | Novo Nordisk sued Hims & H |
| 2026-03-03 | FDA released 30 further wa |
| 2026-03-09 | Hims & Hers settled with N |
| 2026-04-30 | FDA proposed excluding tir |
| 2026-05-01 | Formal notice published at |
| 2026-06-26 | Comment period extended to |
| 2026-07-30 | Comment period closes |
- Retatrutide Phase 3 Results: What Changed in July 2026published
- FDA Compounded GLP-1 Rules in 2026published
- How to Spot Fraudulent Compounded GLP-1 Labelspublished
- Tirzepatide vs Semaglutide: What the Head-to-Head Trial Showspublished
- Cheapest FDA-Approved vs Compounded GLP-1 Optionspublished
- The Oral GLP-1 Landscape in 2026published
- Microdose Tirzepatide: The Evidence Gappublished
- Why Multi-Dose Vials Create Tirzepatide Dosing Errorspublished
- GLP-1 Weight Loss and Muscle Preservationpublished
- What Happens After You Stop Tirzepatide?published
- Tirzepatide and Sleep Apnea: Evidence and FDA Statuspublished
- Tirzepatide and Heart Failure With Preserved Ejection Fractionpublished
- Tirzepatide and Diabetes Prevention Over 176 Weekspublished
- Why Compounded GLP-1 Access Differs by Statepublished
- 503A vs 503B: A Patient Verification Checklistpublished
- How to Verify a Compounding Pharmacy Before You Enrollpublished
- The Hidden Cost of GLP-1 Membership Feespublished
- How Dose Escalation Changes Tirzepatide Costpublished
- Compounded vs Brand Tirzepatide: Legal and Evidence Differencespublished
- How to Verify GLP-1 Claims in AI Search Resultspublished
Within lawful compounding, NexLife is the only provider whose pricing we captured directly — compounded tirzepatide from $186 a month, flat at every covered dose, no membership fee. See its plans.
Questions readers actually ask
How often does the journal publish?
When there is something sourced to say. We do not publish on a schedule, because a publication calendar produces articles whether or not the evidence has moved.
Why are some articles missing?
Three are commissioned but unwritten, and stay noindexed until they carry content worth reading. The retatrutide piece waits on primary-source confirmation of phase 3 figures.
Related on this site
- Retatrutide Phase 3 Results: What Changed in July 2026Journal
- FDA Compounded GLP-1 Rules in 2026Journal
- How to Spot Fraudulent Compounded GLP-1 LabelsJournal
- Tirzepatide vs Semaglutide: What the Head-to-Head Trial ShowsJournal
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Found vs Henry MedsComparisons
- Found Tirzepatide ReviewProviders
- Enhance.MD Tirzepatide ReviewProviders
GLP-1 Tirzepatide Review. “GLP-1 and Tirzepatide Journal.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/journal/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.